We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Hypothesis of First North America Population Updated by Mitochondrial Genome Analysis

By LabMedica International staff writers
Posted on 26 Jul 2010
The first arrival humans of North America from Asia is thought to have occurred approximately 15,000-18,000 years ago, however, estimations of the genetic diversity of the first settlers have remained inaccurate. More...
In a new study, researchers have discovered that the diversity of the first Americans has been considerably underestimated, emphasizing the importance of a detailed sampling for accurate analysis of human migrations.

Evidence suggests that humans first crossed into North America from Asia over a land bridge called Beringia, connecting eastern Siberia and Alaska. Genetic studies have provided clues into the initial lineages that entered North America, differentiating the earliest Native American groups from those that arrived later. However, a precise depiction of the number of initial migratory events and routes has been obscure due to incomplete analysis.

In this new project, published online ahead of print on June 29, 2010, in the journal Genome Research, an international group of researchers coordinated by Dr. Antonio Torroni, of the University of Pavia (Italy), performed a comprehensive mitochondrial genome analysis of a poorly characterized lineage known as C1d. Mitochondrial DNA (mtDNA) is passed down through the maternal lineage, and mtDNA sequence markers are very useful tools for mapping ancestry. Similar to other haplogroups that were among the first to arrive in North America, C1d is distributed throughout the continent, suggesting that it may have been also present in the initial founding populations. However, C1d has not been well represented in earlier genetic studies, and the estimated age of about 7,000 years, much younger than the other founding haplogroups, was in all probability inaccurate.

To resolve these inconsistent lines of evidence, the group sequenced and analyzed 63 C1d mtDNA genomes from throughout the Americas. This high-resolution study not only validated that C1d was one of the founding lineages in North America 15,000-18,000 years ago, but revealed another critical insight. "These first female American founders carried not one but two different C1d genomes,” said Ugo Perego, from the Sorenson Molecular Genealogy Foundation (Salt Lake City, UT, USA), and primary author of the study, "thus further increasing the number of recognized maternal lineages from Beringia.”

These study's findings increase the number of founding maternal lineages in North America to 15. Furthermore, this work emphasizes the vital need for a thorough analysis of applicable populations to compile a complete picture of migratory events. Dr. Alessandro Achilli of the University of Perugia (Italy), a coauthor of the report, suggests that the number of distinct mitochondrial genomes that passed from Asian into North America is probably much higher. "These yet undiscovered maternal lineages will be identified within the next three to four years,” Dr. Achilli noted, "when the methodological approach that we used in our study will be systematically applied.”

Scientists involved in the project were from the Sorenson Molecular Genealogy Foundation, the University of Pavia (Pavia, Italy), the University of Perugia (Perugia, Italy), the University of Santiago de Compostela (Santiago de Compostela, Spain), Innsbruck Medical University (Innsbruck, Austria), and the University of Buenos Aries (Buenos Aires, Argentina).

Related Links:

University of Pavia
Sorenson Molecular Genealogy Foundation




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.